BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Hofler H, Kiechle M, Schmitt M. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol. 2003;21:1022-1028. [PMID: 12637466 DOI: 10.1200/jco.2003.04.170] [Cited by in Crossref: 71] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Deryugina EI, Quigley JP. Cell surface remodeling by plasmin: a new function for an old enzyme. J Biomed Biotechnol 2012;2012:564259. [PMID: 23097597 DOI: 10.1155/2012/564259] [Cited by in Crossref: 87] [Cited by in F6Publishing: 78] [Article Influence: 9.7] [Reference Citation Analysis]
2 Banys-Paluchowski M, Witzel I, Aktas B, Fasching PA, Hartkopf A, Janni W, Kasimir-Bauer S, Pantel K, Schön G, Rack B, Riethdorf S, Solomayer EF, Fehm T, Müller V. The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. Sci Rep 2019;9:2318. [PMID: 30783124 DOI: 10.1038/s41598-018-37259-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
3 Knauer M, Cardoso F, Wesseling J, Bedard PL, Linn SC, Rutgers EJ, van 't Veer LJ. Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Br J Cancer 2010;103:1788-93. [PMID: 21081926 DOI: 10.1038/sj.bjc.6605916] [Cited by in Crossref: 54] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
4 Fang H, Jin J, Huang D, Yang F, Guan X. PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells. Cancer Sci 2018;109:1949-57. [PMID: 29601121 DOI: 10.1111/cas.13593] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
5 Taniguchi K, Iida T, Hori T, Yagi S, Imai H, Shiraishi T, Uemoto S. Impact of lymph node micrometastasis in hilar bile duct carcinoma patients. World J Gastroenterol. 2006;12:2549-2555. [PMID: 16688800 DOI: 10.3748/wjg.v12.i16.2549] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
6 Indira Chandran V, Eppenberger-Castori S, Venkatesh T, Vine KL, Ranson M. HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer. Oncoscience 2015;2:207-24. [PMID: 25897424 DOI: 10.18632/oncoscience.146] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
7 Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res. 2006;8:R61. [PMID: 17069663 DOI: 10.1186/bcr1613] [Cited by in Crossref: 119] [Cited by in F6Publishing: 98] [Article Influence: 8.5] [Reference Citation Analysis]
8 Serce NB, Boesl A, Klaman I, von Serényi S, Noetzel E, Press MF, Dimmler A, Hartmann A, Sehouli J, Knuechel R, Beckmann MW, Fasching PA, Dahl E. Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis. BMC Cancer 2012;12:597. [PMID: 23236990 DOI: 10.1186/1471-2407-12-597] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
9 Offersen BV, Nielsen BS, Høyer-Hansen G, Rank F, Hamilton-Dutoit S, Overgaard J, Andreasen PA. The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol 2003;163:1887-99. [PMID: 14578188 DOI: 10.1016/S0002-9440(10)63547-X] [Cited by in Crossref: 54] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
10 Sternlicht MD, Dunning AM, Moore DH, Pharoah PD, Ginzinger DG, Chin K, Gray JW, Waldman FM, Ponder BA, Werb Z. Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev 2006;15:2107-14. [PMID: 17119035 DOI: 10.1158/1055-9965.EPI-06-0351] [Cited by in Crossref: 41] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
11 Dovnik NF, Takac I. Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients. Radiol Oncol 2017;51:65-73. [PMID: 28265234 DOI: 10.1515/raon-2016-0024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
12 Witzel I, Milde-Langosch K, Schmidt M, Karn T, Becker S, Wirtz R, Rody A, Laakmann E, Schütze D, Jänicke F, Müller V. Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer. Onco Targets Ther 2014;7:2205-13. [PMID: 25506225 DOI: 10.2147/OTT.S65344] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
13 Sylman JL, Mitrugno A, Tormoen GW, Wagner TH, Mallick P, McCarty OJT. Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer. Converg Sci Phys Oncol 2017;3:023001. [PMID: 29081989 DOI: 10.1088/2057-1739/aa6c05] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
14 Nolen BM, Marks JR, Ta'san S, Rand A, Luong TM, Wang Y, Blackwell K, Lokshin AE. Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res 2008;10:R45. [PMID: 18474099 DOI: 10.1186/bcr2096] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
15 Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res 2004;6:109-18. [PMID: 15084231 DOI: 10.1186/bcr777] [Cited by in Crossref: 144] [Cited by in F6Publishing: 120] [Article Influence: 8.5] [Reference Citation Analysis]
16 El-Fattah AAA, Sadik NAH, Shaker OG, Mohamed Kamal A, Shahin NN. Serum Long Non-Coding RNAs PVT1, HOTAIR, and NEAT1 as Potential Biomarkers in Egyptian Women with Breast Cancer. Biomolecules 2021;11:301. [PMID: 33670447 DOI: 10.3390/biom11020301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Lampelj M, Arko D, Cas-Sikosek N, Kavalar R, Ravnik M, Jezersek-Novakovic B, Dobnik S, Dovnik NF, Takac I. Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors. Radiol Oncol 2015;49:357-64. [PMID: 26834522 DOI: 10.2478/raon-2014-0049] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
18 Schmidt M, Lewark B, Kohlschmidt N, Glawatz C, Steiner E, Tanner B, Pilch H, Weikel W, Kölbl H, Lehr HA. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res 2005;7:R256-66. [PMID: 15743506 DOI: 10.1186/bcr991] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
19 Goldstein LJ. Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer. Breast Care (Basel) 2008;3:25-8. [PMID: 20824011 DOI: 10.1159/000151733] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
20 Denkert C, Kronenwett R, Schlake W, Bohmann K, Penzel R, Weber KE, Höfler H, Lehmann U, Schirmacher P, Specht K. Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch. 2012;460:251-259. [PMID: 22371223 DOI: 10.1007/s00428-012-1204-4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 6.8] [Reference Citation Analysis]
21 Gramling MW, Church FC. Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thromb Res 2010;125:377-81. [PMID: 20079523 DOI: 10.1016/j.thromres.2009.11.034] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
22 Harbeck N, Schmitt M, Vetter M, Krol J, Paepke D, Uhlig M, Paepke S, Jänicke F, Geurts-Moespot A, von Minckwitz G, Sweep F, Thomssen C. Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer. Breast Care (Basel) 2008;3:11-5. [PMID: 20824008 DOI: 10.1159/000151734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]